No Link Between Coronary Issues, Two-Dose Hepatitis B Vaccine
While a prelicensure clinical trial of HEPLISAV-B, the two-dose adult hepatitis B vaccine, found an unanticipated numerical imbalance in acute myocardial infarction (AMI) compared with another vaccine, that was not born out in later trials. A trial found that the hazard ratio comparing the rate of AMI in the HEPLISAV-B group with the Engerix-B group was 0.92 with a 95% confidence interval of 0.63 to 1.32. Here is more information.
|